You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
力生製藥(002393.SZ):通過合成生物學新賽道與中科院工生所合作開展“鯤01”“鯤02”項目研究

格隆匯6月16日丨力生製藥(002393.SZ)在互動平臺表示,截止2025年6月10日公司股東人數爲21424。公司在創新藥研發方面積極佈局,通過實施“內生外引”戰略,採取自主研發、合作開發、許可引進及CMO孵化等多元化模式,推進高端仿製藥、創新藥、合成生物學、細胞與基因治療等領域的業務發展,致力於向更高價值鏈延伸。具體來看,公司重點佈局緩控釋技術平臺,並已在吲達帕胺緩釋片、甲磺酸多沙唑嗪緩釋片等高端仿製藥品種上取得藥品註冊證書,同時通過合成生物學新賽道與中科院工生所合作開展“鯤01”“鯤02”項目研究。此外,公司還拓展細胞與基因治療業務,完善原料藥-製劑一體化佈局,強化產業鏈協同,提升技術壁壘和產品附加值。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account